Squamous cell carcinoma of the penis is a rare but serious malignancy that accounts for the vast majority of penile cancers, arising from the flat cells lining the skin of the penis. Globally, roughly 36,000 new cases and over 13,000 deaths were estimated in 2020, with incidence varying dramatically by region. Because the disease is uncommon in high-income countries, it receives comparatively little research attention and public awareness, yet it can be devastating when diagnosed late. The biology, treatment landscape, and human toll of this cancer are all more complex than its rarity might suggest.
How Common Is It, and Where?
Penile cancer is not distributed evenly around the world. South America reports the highest incidence, while rates in North America and much of Europe remain low. The global age-standardized incidence rate sits at about 0.80 per 100,000 men, with an age-standardized mortality rate of roughly 0.29 per 100,000. Those numbers may sound small, but they mask stark regional differences: in parts of sub-Saharan Africa, South Asia, and South America, penile cancer can account for a meaningful share of male malignancies.
Interestingly, incidence is rising in a number of countries. A population-based study found increasing rates in 15 nations, 13 of them in Europe, including the United Kingdom, the Netherlands, and several Nordic and Eastern European countries, along with China and Israel in Asia. The reasons are debated but may relate to changing sexual behaviors, shifts in circumcision practices, and improved cancer registration capturing cases previously missed.
What Raises the Risk
Several well-established risk factors converge around chronic irritation, infection, and impaired local immunity. The major ones include phimosis (a tight foreskin that cannot be fully retracted), lack of circumcision, lichen sclerosus (a chronic inflammatory skin condition), human papillomavirus (HPV) infection, smoking, obesity, prior ultraviolet-A phototherapy, compromised immune function, and lower socioeconomic status. Many of these factors overlap. A man with phimosis, for instance, is more likely to develop lichen sclerosus, and both conditions create an environment of chronic inflammation that can eventually tip cells toward malignancy.
Lichen sclerosus deserves particular attention because it is found surprisingly often in men undergoing surgery for phimosis. One study of patients with clinically significant phimosis found lichen sclerosus in nearly half of surgical specimens, and malignant disease was present in about 4% of those with lichen sclerosus compared to roughly 3% without it. The difference may seem modest, but lichen sclerosus is a treatable condition, and recognizing it early can prompt closer surveillance.
Two Roads to Cancer
Not all penile squamous cell carcinomas develop the same way. Research has identified two major molecular pathways. The first is driven by HPV. In these tumors, the virus integrates into the host cell’s DNA and produces proteins that disable normal growth controls, leading to overexpression of a protein called p16. The second pathway is HPV-independent and typically arises in the setting of chronic skin conditions like lichen sclerosus. In these tumors, the TP53 gene, which normally acts as a brake on uncontrolled cell growth, accumulates disabling mutations. These HPV-negative cancers express abnormal p53 but lack p16 overexpression.
A study examining 76 penile squamous cell carcinomas classified about 57% as HPV-induced based on the presence of HPV DNA and p16 overexpression, while 43% were HPV-negative. Among the HPV-negative group, roughly three-quarters carried mutations in the TP53 gene. This distinction matters beyond academic interest: HPV-related and HPV-independent tumors can behave differently, and some histologic subtypes linked to HPV tend to carry a better prognosis.
Precancerous Changes and How They Progress
Penile squamous cell carcinoma does not usually appear out of nowhere. It is often preceded by precancerous changes collectively called penile intraepithelial neoplasia, or PeIN. Bowen’s disease is one well-known form that typically affects men over 50 and is defined by abnormal cells confined within the skin’s upper layer. These lesions carry the potential to progress into invasive cancer if left untreated.
A Dutch registry study of 380 patients with premalignant penile lesions found that most lesions occurred on the foreskin or glans. The median age at diagnosis was 58 years. Progression to invasive cancer occurred in a small but meaningful fraction of patients, with higher-grade lesions carrying greater risk: about 7% of high-grade lesions progressed compared to roughly 2% of low-grade ones. These numbers reinforce the value of treating or closely monitoring precancerous changes rather than assuming they are harmless.
Staging the Primary Tumor
Once a biopsy confirms squamous cell carcinoma, the next step is determining how deeply the cancer has invaded and whether it has spread. Physical examination remains the starting point, but imaging plays an important role for surgical planning. MRI has shown reasonable accuracy for assessing whether the tumor has invaded the tunica albuginea, the tough fibrous sheath surrounding the erectile tissue. One study found MRI had about 82% sensitivity and 74% specificity for detecting tunica albuginea invasion, though it was less sensitive for assessing urethral involvement. These findings support using MRI to help guide decisions about how much tissue needs to be removed while avoiding unnecessary amputation.
Checking the Lymph Nodes
Lymph node status is the single most important factor in predicting whether a man with penile cancer will survive his disease. The inguinal (groin) lymph nodes are the first stop for cancer cells spreading from the penis, and involvement of these nodes dramatically worsens the outlook. The challenge is that many men with clinically impalpable nodes still harbor microscopic disease, while some with enlarged nodes have only reactive inflammation, not cancer.
Dynamic sentinel node biopsy has emerged as a way to check for hidden lymph node involvement without subjecting every patient to a full groin dissection, which carries significant complications. A study evaluating this technique found a detection rate of about 91% per procedure, with a sensitivity of 79% and a negative predictive value of 97%. In a smaller case series from Southeast Asia, the technique allowed over 60% of groins to avoid a full inguinal lymph node dissection in men with no palpable nodes, with no false negatives over the follow-up period. These results support dynamic sentinel node biopsy as a reasonable middle ground for men at intermediate or high risk whose groins feel clinically normal.
When a full inguinal lymph node dissection is necessary, the complication rate rises substantially. One series reported early complications in over 40% of radical procedures and late complications, mainly chronic leg swelling, in a similar proportion. A modified technique sparing the saphenous vein and limiting the extent of dissection showed much lower complication rates and is generally preferred when nodes are not clinically suspicious. Decisions about whether to also dissect the deeper pelvic nodes depend on how many inguinal nodes are involved: patients with only one or two positive inguinal nodes without extracapsular growth have roughly a 90% five-year survival and may be spared pelvic dissection entirely.
Organ-Sparing Surgery
Historically, partial or total penectomy was the default surgical approach, but the psychological and functional toll of losing part or all of the penis has driven a shift toward organ-sparing techniques for appropriate candidates. These include wide local excision, glans resurfacing, laser ablation, and Mohs micrographic surgery, among others. Organ-sparing surgery aims to remove the cancer while preserving as much penile length and function as possible.
A systematic review found that while organ-sparing surgery carries a greater risk of local recurrence than amputation, overall survival is generally unaffected. This somewhat counterintuitive finding holds because local recurrences can usually be caught and retreated with further surgery, and they do not appear to increase the risk of distant spread when followed closely. A separate institutional study confirmed that organ-sparing surgery was associated with higher local recurrence but had no negative impact on overall survival or metastasis-free survival. For men with low-stage disease, the evidence supports organ-sparing approaches as a first-line option, provided they commit to rigorous follow-up.
When cancer is more advanced or located proximally on the shaft, partial or total penectomy remains necessary. These more extensive procedures still have a role in achieving clear margins and controlling disease that cannot be safely managed with tissue-sparing methods.
Radiation as an Alternative
Radiation therapy, particularly brachytherapy (where a radioactive source is placed directly against or into the tumor), offers another path to organ preservation. Brachytherapy is best suited for tumors limited to the glans and smaller than about four centimeters. A large multicenter retrospective study reported five-year local control of 86%, penile preservation of 85%, and overall survival of 82% with brachytherapy. Late side effects included urethral narrowing in about 18% of patients, and the study found that men who had been circumcised before treatment had significantly lower rates of serious acute side effects.
A broader review comparing radiation approaches found that brachytherapy showed roughly 73% amputation-free survival at eight to ten years and 81% progression-free survival at five to ten years. External beam radiation is an alternative when brachytherapy is not feasible, though brachytherapy tends to offer better local control and organ preservation rates. Common acute side effects of radiation include skin irritation and inflammation of the urethra, while the main long-term concerns are soft tissue breakdown and narrowing of the urethral opening. For well-selected patients, radiation can achieve cancer control rates comparable to surgery while sparing the organ.
Chemotherapy for Advanced Disease
When penile cancer spreads to lymph nodes or beyond, systemic chemotherapy enters the picture. The most studied regimen combines paclitaxel, ifosfamide, and cisplatin, commonly called TIP. A phase II trial of 30 men with metastatic disease found that half achieved an objective response, and about 73% were able to proceed to surgery afterward. Roughly 30% of patients remained alive and free of recurrence at a median follow-up of nearly three years. Responding to chemotherapy was strongly linked to better outcomes, underscoring that TIP can convert otherwise inoperable disease into a surgically manageable situation for a meaningful number of patients.
Still, the overall picture for advanced penile cancer remains sobering. Response rates to combination chemotherapy generally fall below 50%, and the treatment carries considerable toxicity. A single-center experience with TIP reported a median overall survival of only six months, though patients who responded to treatment survived significantly longer than those who did not. The gap between responders and non-responders highlights how variable this disease can be once it has spread.
Immunotherapy and Newer Approaches
Given the limitations of chemotherapy, researchers have turned to immune checkpoint inhibitors. Pembrolizumab, a drug that helps the immune system recognize and attack cancer cells, has been tested in small studies of advanced penile squamous cell carcinoma. Early results with pembrolizumab alone were modest: responses were seen mainly in tumors with a specific molecular feature called microsatellite instability, while patients without that feature experienced rapid disease progression. This finding suggests that single-agent immunotherapy has a role only in a small subset of patients.
More encouraging results have come from combining pembrolizumab with platinum-based chemotherapy. A clinical trial reported an overall response rate of about 39% among 33 evaluable patients, with one complete response and twelve partial responses. While these numbers are not transformative, they represent meaningful activity in a disease with very few systemic options and point toward combination strategies as the more promising direction for future research.
What Drives Prognosis
The outlook for penile squamous cell carcinoma depends heavily on a handful of factors. Lymph node involvement stands out as the dominant predictor. A systematic review confirmed that lymph node metastasis is associated with markedly worse survival. Among patients whose cancer has spread beyond the lymph node capsule, the prognosis is especially grim: one study found that extensive extranodal extension was independently associated with a roughly six-fold increase in the risk of death.
The histologic subtype of the tumor also matters. A large registry-based study found that five-year cancer-specific survival was highest for certain variant subtypes, particularly verrucous carcinoma at about 94%, compared to roughly 74% for the usual subtype. Verrucous carcinoma was independently associated with significantly lower cancer-specific mortality. Sarcomatoid variants, on the other hand, carried the worst outcomes at around 63% five-year survival. These distinctions can help clinicians tailor the intensity of treatment and surveillance.
Prevention Strategies
Neonatal circumcision has long been recognized as protective against penile cancer, likely because it eliminates phimosis and reduces the conditions that promote chronic inflammation and HPV persistence. The evidence for this is consistent enough that some researchers argue circumcision should be part of the conversation around genital cancer prevention, though it remains a culturally and ethically complex recommendation.
HPV vaccination is a more straightforward preventive measure, yet its specific impact on penile cancer is not well established. HPV vaccines are expected to reduce HPV-related cancers broadly, and given that over half of penile squamous cell carcinomas are HPV-driven, vaccination of boys could plausibly reduce incidence. However, direct evidence proving that HPV vaccination prevents penile cancer is still lacking, and further research is needed to quantify the benefit. In the meantime, vaccination remains strongly recommended for other HPV-related diseases, and any protective effect against penile cancer would be an additional benefit.
Life After Treatment
The physical and psychological aftermath of penile cancer treatment is often underappreciated. A systematic review of quality-of-life studies found impaired well-being in up to 40% of patients across multiple measures, with rates of clinical anxiety reaching 31%. One study using psychiatric diagnostic criteria found that over half of patients exhibited signs of mental illness, and 40% of a cohort met criteria for post-traumatic stress disorder. More mutilating treatments were consistently linked to worse psychological outcomes.
Sexual function is predictably affected, though the degree depends on the type of surgery. After laser treatment or glans resurfacing for early-stage disease, sexual function and satisfaction tend to be only modestly reduced, and patient-reported cosmetic outcomes are generally positive. After partial penectomy, results are more variable: some studies report that a third of men have no remaining sexual function, while others find that a majority retain the ability to achieve erections, albeit with reduced satisfaction. After total penectomy, functional restoration is currently not achievable, though cosmetically acceptable reconstruction is possible. The limited data on sexual rehabilitation after radical treatment point to a significant unmet need in supportive care for these patients.
Surveillance After Organ-Sparing Treatment
Men who undergo organ-sparing surgery face a higher risk of local recurrence than those who have more radical procedures, which makes close follow-up essential. The reassuring finding from multiple studies is that this higher recurrence rate does not translate into worse overall or metastasis-free survival, as long as recurrences are caught and managed promptly. Repeated organ-sparing surgery can be considered for selected cases of local recurrence, preserving the organ a second time around.
When cancer recurs in the groin lymph nodes after initial treatment, the situation is more challenging. Salvage inguinal lymph node dissection can be curative for isolated local recurrences, provided there is no hidden disease elsewhere. However, patients considering this salvage surgery should be aware that the likelihood of postoperative complications is high. The decision to pursue salvage surgery versus other approaches must weigh the real chance of cure against the substantial morbidity of reoperation in a previously treated groin.
Stigma and Delayed Diagnosis
Perhaps the most frustrating aspect of penile cancer is how often it is diagnosed late. Men frequently delay seeking medical attention for penile lesions, sometimes for months or even years. The reasons are deeply rooted in stigma, embarrassment, and fear. A recent commentary in a major cancer journal identified stigma as the primary driver of delay among undiagnosed patients and called for focused public health campaigns to improve awareness and reduce the shame associated with genital symptoms.
This delay matters enormously because outcomes are closely tied to stage at diagnosis. A man whose cancer is caught while still confined to the skin has an excellent prognosis with organ-sparing treatment, while a man who presents with bulky lymph node disease faces a far grimmer reality despite aggressive multimodal therapy. Any persistent lesion on the penis, whether a lump, ulcer, discolored patch, or area of thickened skin, warrants prompt medical evaluation. The barrier is not medical complexity but human reluctance to discuss a topic that remains deeply taboo.